Digestive Diseases and Sciences

, Volume 59, Issue 6, pp 1231–1234 | Cite as

Granisetron Transdermal System Improves Refractory Nausea and Vomiting in Gastroparesis

  • Kellie Simmons
  • Henry P. ParkmanEmail author
Original Article



Symptoms of gastroparesis include nausea and vomiting, which can markedly diminish quality of life. Nausea and vomiting can also make treatment with oral antiemetics problematic.


Our aim was to determine whether treatment-resistant nausea and vomiting in patients with gastroparesis improve after granisetron transdermal patch (GTP) therapy.


In an open-label pilot study, patients with gastroparesis and symptoms of nausea and vomiting refractory to conventional treatment were treated with GTP. After 2 weeks, patients were asked to assess their therapeutic response using the Clinical Patient Grading Assessment Scale (CPGAS; +7 = completely better; 0 = no change; −7 = very considerably worse). Responders were defined as CPGAS score >0, non-responders as ≤0.


Patients (n = 36) were treated with GTP. Of these 36 patients, one patient discontinued treatment due to the GTP not adhering to the skin. Of the remaining 35 patients, 18 improved, 15 remained the same, and two worsened. The average CPGAS score was +1.8 ± 0.4 (SEM) (P < 0.05 vs 0). Of the 18 patients with improvement, the average CPGAS score was +3.7 ± 0.3 (SEM), corresponding to “somewhat” to “moderately better” improvement in nausea/vomiting. Side effects occurred in nine patients: four developed constipation, three patients had skin rash, and two reported headaches.


GTP was moderately effective in reducing refractory symptoms of nausea and/or vomiting from gastroparesis in 50 % of patients. Mild side effects were reported by 25 % of patients. GTP may be an effective treatment for nausea and vomiting in gastroparesis, and further study is warranted.


Granisetron Gastroparesis Nausea Vomiting 



Granisetron transdermal patch


Gastric emptying scintigraphy


Clinical Patient Grading Assessment Scale


Gastroparesis Cardinal Symptom Index


GCSI daily diary


Standard error of the mean


Standard deviation


Conflict of interest

Henry Parkman has served as a consultant and on a product advisory board for ProStrakan, Inc., makers of Sancuso®. Kellie Simmons has nothing to disclose.


  1. 1.
    Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622.PubMedCrossRefGoogle Scholar
  2. 2.
    Cherian D, Parkman HP. Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterol Motil. 2012;24:e103.CrossRefGoogle Scholar
  3. 3.
    Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18–37.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263–283.PubMedCrossRefGoogle Scholar
  5. 5.
    Hasler WL. Serotonin and the GI tract. Curr Gastroenterol Rep. 2009;11:383–391.PubMedCrossRefGoogle Scholar
  6. 6.
    Keating GM, Duggan ST, Curran MP. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy. CNS Drugs. 2012;26:787–790.PubMedCrossRefGoogle Scholar
  7. 7.
    Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95:1456–1462.PubMedCrossRefGoogle Scholar
  8. 8.
    Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008;103:753–763.PubMedCrossRefGoogle Scholar
  9. 9.
    Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol. 2011;9:567–576.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Parkman HP, Mishra A, Jacobs M, et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494–503.PubMedCrossRefGoogle Scholar
  11. 11.
    Jaffe JK, Paladugu S, Gaughan JP, et al. Characteristics of nausea and its effects on quality of life in diabetic and idiopathic gastroparesis. J Clin Gastroenterol. 2011;45:317–321.PubMedCrossRefGoogle Scholar
  12. 12.
    Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064.PubMedCrossRefGoogle Scholar
  13. 13.
    Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2009;13:711–714.PubMedCrossRefGoogle Scholar
  14. 14.
    Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19:1609–1617.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    A granisetron patch (Sancuso). Med Lett Drugs Ther. 2008;50:103–104.Google Scholar
  16. 16.
    Amin K, Bastani B. Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis. Perit Dial Int. 2002;22:539–540.PubMedGoogle Scholar
  17. 17.
    El-Gammal A, Rashed HM, Taylor J, et al. Long term ondansetron therapy is beneficial in patients with chronic nausea and vomiting [abstract]. Gastroenterology. 2000;118:A1170.CrossRefGoogle Scholar
  18. 18.
    Nielsen OH, Hvid-Jacobsen K, Lund P, et al. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion. 1990;46:89–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–150.PubMedCrossRefGoogle Scholar
  20. 20.
    Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-daily diary (GCSI-DD). Neurogastroenterol Motil. 2012;24:456–463.PubMedCrossRefGoogle Scholar
  21. 21.
    Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci. 2008;53:2072–2078.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.GI Section, Section of Gastroenterology, Department of Medicine, Temple University School of MedicineTemple University HospitalPhiladelphiaUSA

Personalised recommendations